Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of NASDAQ EGRX opened at $0.52 on Monday. Eagle Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $6.81. The business has a fifty day moving average of $0.72 and a two-hundred day moving average of $3.04.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. DGS Capital Management LLC raised its stake in shares of Eagle Pharmaceuticals by 44.9% in the third quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock valued at $268,000 after acquiring an additional 22,239 shares during the last quarter. Jane Street Group LLC bought a new position in Eagle Pharmaceuticals in the 3rd quarter valued at $96,000. RBF Capital LLC raised its position in Eagle Pharmaceuticals by 11.7% in the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after purchasing an additional 14,991 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Eagle Pharmaceuticals in the third quarter worth $453,000. Finally, Creative Planning bought a new stake in shares of Eagle Pharmaceuticals during the third quarter worth $59,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.